Endothelin receptor antagonist
An endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors.
Three main kinds of ERAs exist:
- selective ETA receptor antagonists (sitaxentan, ambrisentan, atrasentan, BQ-123, zibotentan), which affect endothelin A receptors.
- dual antagonists (bosentan, macitentan, tezosentan), which affect both endothelin A and B receptors.[1]
- selective ETB receptor antagonists (BQ-788 and A192621) which affect endothelin B receptors are used in research but have not yet reached the clinical trial stage.
Sitaxentan, ambrisentan and bosentan are mainly used for the treatment of pulmonary arterial hypertension, while atrasentan is an experimental anti-cancer drug.
Edonentan is an endothelin receptor antagonist drug.
References
| Prostacyclin analogues | |
|---|---|
| Endothelin receptor antagonists | |
| PDE5 inhibitors | |
| sGC stimulators | |
| Adjunctive therapy | |
| Sympatholytics (antagonize α-adrenergic vasoconstriction) |
| ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other antagonists |
| ||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.